ClinicalTrials.gg

Program

foslinanib

Also written as “CVM-1118”, “CVM-1118 + Sintilimab + TACE” and “CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)”.

Its studies are mostly in Carcinoma, Hepatocellular · Neuroendocrine Tumors · Neoplasms, led by TaiRx.

Furthest: phase 2, since May 21, 20185 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TaiRx53 open or runningphase 2since May 21, 2018May 21, 2018Dec 31, 2026phase 2 · NCT05257590

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 21, 2018First study: phase 2 study in Carcinoma, HepatocellularFirst studyNCT03582618 · 12 enrolled · United States, Taiwan
  2. Jun 7, 2018Phase 2 study in Neuroendocrine TumorsNCT03600233 · 34 enrolled · Taiwan
  3. Mar 31, 2020Phase 1 study in NeoplasmsNCT04336124 · 5 enrolled · Taiwan
  4. Feb 8, 2022Phase 2 study in Carcinoma, HepatocellularNCT05257590 · 95 planned · Taiwan
  5. Mar 31, 2026Phase 2 study in Carcinoma, HepatocellularNCT07521852 · 40 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Carcinoma, HepatocellularNCT05257590
  2. Dec 31, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07521852

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07521852Carcinoma, Hepatocellular · China2RecruitingDec 31, 202740
NCT05257590Carcinoma, Hepatocellular · Taiwan2RecruitingDec 31, 202695
NCT04336124Neoplasms · Taiwan1CompletedFeb 8, 20215
NCT03600233Neuroendocrine Tumors · Taiwan2Active, not recruitingSep 30, 202434
NCT03582618Carcinoma, Hepatocellular · United States, Taiwan2TerminatedNov 16, 202112

How it is read

Names in the registry

  • “CVM-1118”, 3 entries
  • “CVM-1118 + Sintilimab + TACE”, 1 entry
  • “CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.